Mass production of the artificial blood vessel by Jiangsu Bioda Life Science Co Ltd, which is based in Chongchuan district, Nantong, East China's Jiangsu province, recently commenced, local media reported. 

Located in the Shibei High-tech Zone in Chongchuan district, Nantong, East China's Jiangsu province, Bioda is the first enterprise in China to mass produce artificial blood vessels. 

The enterprise has been focusing its efforts on the research and development of artificial blood vessels in recent years. Last November, Bioda's self-developed artificial blood vessel – VASOLINE – was approved for sale by the National Medical Products Administration, or NMPA. 

The product launch will break the 60-year monopoly that foreign giants have over artificial blood vessels, said Du Guangwei, the general manager of Bioda.

To boost the production capacity of the enterprise, zone authorities have provided Bioda with 50,000 square meters of industrial land on which it will build a new production base. 

Following the completion of the new base, the enterprise is expected to produce 60,000 artificial blood vessels annually. 

The enterprise is expected to command a domestic market share of at least 50 percent following mass production, Du added. 

A model of the artificial blood vessel developed by Jiangsu Bioda Life Science Co Ltd. [Photo/WeChat account: chongchuanonline]